Search results
Results from the WOW.Com Content Network
The bad news: Its stock was down more than 10% in early trading, largely because of weaker-than-expected 2025 guidance. Merck reported $64.2 billion in sales for 2024, a 7% increase compared with ...
On Monday, Merck & Co Inc (NYSE:MRK) revealed topline results from the Phase 3 ZENITH study evaluating Winrevair (sotatercept-csrk) in adults with pulmonary arterial hypertension (PAH, WHO Group 1 ...
Merck (MRK) closed at $86.95 in the latest trading session, marking a +0.78% move from the prior day.
On Monday, Merck & Co Inc (NYSE:MRK) announced the notice of the mutual exercise of an option to convert the companies’ ongoing co-development and co-commercialization agreement for opevesostat ...
Merck (MRK) closed the most recent trading day at $88, moving -1.65% from the previous trading session.
Zacks.com users have recently been watching Merck (MRK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects. Investors Heavily Search Merck & Co., Inc. (MRK ...
On Thursday, the U.S. Centers for Disease Control and Prevention’s (CDC’s) Advisory Committee on Immunization Practices (ACIP) unanimously voted to recommend Merck & Co Inc’s (NYSE:MRK ...
Even with that growth, the stock still trades at a fairly modest valuation. Its stock price is up 5.3% this year, compared with 16% growth for the S&P 500. Why isn't Merck's stock doing better in ...